Allarity Therapeutics Announces Executive and Board Changes
Ticker: ALLR · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1860657
Sentiment: neutral
Topics: executive-changes, board-changes, personnel
TL;DR
Allarity Therapeutics shakes up leadership: new CMO appointed, board changes announced.
AI Summary
On September 30, 2024, Allarity Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The company also announced the appointment of Dr. Anders M. Holmberg as Chief Medical Officer and the resignation of Dr. Steve R. Saklad from the same role. Additionally, the filing includes information on compensatory arrangements for certain officers.
Why It Matters
Changes in key leadership roles can signal shifts in company strategy or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and execution, warranting closer monitoring.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- Dr. Anders M. Holmberg (person) — Appointed Chief Medical Officer
- Dr. Steve R. Saklad (person) — Resigned as Chief Medical Officer
- September 30, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer for Allarity Therapeutics?
Dr. Anders M. Holmberg has been appointed as the new Chief Medical Officer.
Who resigned from the position of Chief Medical Officer?
Dr. Steve R. Saklad resigned from the position of Chief Medical Officer.
What is the exact date of the reported event?
The earliest event reported is dated September 30, 2024.
What type of filing is this for Allarity Therapeutics?
This is a Form 8-K filing, a current report.
What are the main topics covered in this 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and other events.
Filing Stats: 1,427 words · 6 min read · ~5 pages · Grade level 11.3 · Accepted 2024-10-04 08:00:34
Key Financial Figures
- $0.0001 — ch registered Common Stock , par value $0.0001 per share ALLR The Nasdaq Stock Mark
- $475,000 — Employment Agreement provides for (i) a $475,000 annual base salary (the "Base Salary"),
- $250,000 — (the "RSUs") with an aggregate value of $250,000; the number of shares to be granted is
- $75,000 — n) and, (v) a one-time signing bonus of $75,000 in exchange for Dr. Graff's promise to
Filing Documents
- allr20241002_8k.htm (8-K) — 39KB
- ex_729373.htm (EX-10.1) — 122KB
- ex_729382.htm (EX-99.1) — 21KB
- atlogosmall.jpg (GRAPHIC) — 6KB
- 0001437749-24-030661.txt ( ) — 361KB
- allr-20240930.xsd (EX-101.SCH) — 3KB
- allr-20240930_def.xml (EX-101.DEF) — 12KB
- allr-20240930_lab.xml (EX-101.LAB) — 16KB
- allr-20240930_pre.xml (EX-101.PRE) — 12KB
- allr20241002_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 3, 2024, the Company, among other things, announced the appointment of Dr. Graff, as the President and Chief Development Officer of the Company.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Employment Agreement, dated as of September 30, 2024, by and between Allarity Therapeutics, Inc., and Jeremy R. Graff. 99.1 Press Release, dated October 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: October 4, 2024 By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer